Synthesis and structureactivity relationship of novel conformationally restricted analogues of serotonin as 5-HT6 receptor ligands

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 3, 2012, Pages 443-450

  Nirogi, Ramakrishna V S ^a   Kambhampati, Ramasastri ^a   Kothmirkar, Prabhakar ^a   Konda, Jagadishbabu ^a   Bandyala, Thrinath Reddy ^a   Gudla, Parandhama ^a   Arepalli, Sobhanadri ^a   Gangadasari, Narasimhareddy P ^a   Shinde, Anil K ^a   Deshpande, Amol D ^a   Dwarampudi, Adireddy ^a   Chindhe, Anil K ^a   Dubey, Pramod Kumar ^b  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

5 HT6; Cognition; Heck reaction; NORT; Serotonin

Indexed keywords

2 FLUORO 10 (2 N,N DIMETHYLAMINOETHYL)ISOINDOLO[2,1 A]INDOLE; 2 PHENYL 10 (2 N,N DIMETHYLAMINOETHYL)ISOINDOLO[2,1 A]INDOL 5 ONE; SEROTONIN 6 RECEPTOR; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LIGAND; SEROTONIN; SEROTONIN RECEPTOR;

AMNESIA; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COGNITION; CONTROLLED STUDY; DRUG BINDING; DRUG CONFORMATION; DRUG DESIGN; DRUG PENETRATION; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; LIGAND BINDING; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; CHEMISTRY; CONFORMATION; DOSE RESPONSE; METABOLISM;

ANIMALIA;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR CONFORMATION; RECEPTORS, SEROTONIN; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860386330     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.595713     Document Type: Article

References (30)

1. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203. (Pubitemid 24185150)
2. Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;46:2795-2812.
3. Brian JJ, Thomas PB. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002;71:555-568.
4. Christopher NJ, Mahmood A, Neil DM. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Curr Opinion Drug Dis Dev 2008;11:642-654.
5. Holenz J, Pauwels PJ, Díaz JL, Mercè R, Codony X, Buschmann H. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov Today 2006;11:283-299.
6. Liu KG, Robichaud AJ. 5-HT6 medicinal chemistry. Int Rev Neurobiol 2010;94:1-34.
7. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008;117:207-231.
8. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer s disease. Neurotherapeutics 2008;5:458-469. (Pubitemid 351952494)
9. Witty D, Ahmed M, Chuang TT. Advances in the design of 5-HT6 receptor ligands with therapeutic potential. Prog Med Chem 2010;48:161-224.
10. Rossé G, Schaffhauser H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr Top Med Chem 2010;10:207-221.
11. Robichaud AJ. Identification of SAM-531 (WAY-262531), a selective 5-HT6 antagonist for the treatment of cognitive dysfunction associated with schizophrenia and Alzheimer s disease. 239th ACS National Meeting and Exposition. San Francisco, CA, MEDI-34, 21-25 March 2010.
12. Johnson CN. The impact of PET on the discovery of 742457, a brainpenetrant 5-HT6 receptor antagonist for symptomatic treatment of Alzheimer s disease. CHI 13th International Molecular Medicine Triconference, San Francisco, USA, 2006.
13. Chuang A, Foley A, Pugh PL. 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer s disease. Alzheimers Dement 2006;2:S631.
14. Mancinelli A. Pharmacokinetics of 5-HT6 receptor ligands. Int Rev Neurobiol 2010;94:153-172.
15. Pineiro-Nunez MM, Bauzon DD, Bymaster FP, Chen Z, Chernet E, Clay MP et al. Discovery and SAR studies of 2,6- difluorobenzenesulfonic acid 1-methyl-3-(1-methylpiperidin-4- yl)-1H-indol-5-yl ester, a novel and potent 5-HT6 antagonist for the treatment of cognitive deficit. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, MEDI-282, 13-17 March 2005.
16. Arnt J, Andersen BB, Bymaster FP, Chohen MP. 2nd Biennial Schizophrenia International Research Conference (SIRS), Florence, Italy, 10-14 April 2010.
17. Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Jasti V. Human phase-1 Multiple Ascending Dose (MAD) study, safety, tolerability and pharmacokinetics of SUVN-502, a 5-HT6 receptor antagonist. Alzheimers Dement 2009;5:250-251.
18. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE et al. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem 2000;43:1011-1018. (Pubitemid 30152305)
19. Russell MG, Baker RJ, Barden L, Beer MS, Bristow L, Broughton HB et al. N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands. J Med Chem 2001;44:3881-3895. (Pubitemid 33051478)
20. Mooradian A, Dupont PE, Hlavec AG, Aceto MD, Pearl J. 3-Aminotetrahydrocarbazoles as a new series of central nervous system agents. j Med Chem 1977;20:487-492. (Pubitemid 8065699)
21. Abate C, Kolanos R, Dukat M, Setola V, Roth BL, Glennon RA. Interaction of chiral MS-245 analogs at h5-HT6 receptors. Bioorg Med Chem Lett 2005;15:3510-3513. (Pubitemid 40942044)
22. Demchyshyn LL, Wilson JM, Maclean NA, Wang H, Black C, DeLannoy I et al. ALX-1161: pharmacological properties of a potent and selective 5-HT6 receptor antagonist. 31st Annual Meeting of the Society for Neuroscience, San Diego, CA, 2001.
23. Slassi A, Edwards L, O Brien A, Xin T, Tehim A. Preparation of 3-(2- pyrrolidinylmethyl)indoles as 5-HT6 antagonists. WO 9947516.
24. Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM et al. A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands. Bioorg Med Chem Lett 2008;18: 3929-3931.
25. Cole DC, Lennox WJ, Stock JR, Ellingboe JW, Mazandarani H, Smith DL et al. Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2005;15:4780-4785. (Pubitemid 41354804)
26. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988;31:47-59.
27. Speeter ME, Anthony WC. The action of oxalyl chloride on indoles: a new approach to tryptamines. J Am Chem Soc 1954;76:6208-6210.
28. Heck RF. Arylation, methylation and carboxyalkylation of olefines by Group VIII metal derivatives. J Am Chem Soc 1968;90:5518-5526.
29. Heck RF, Noley JP Jr. Palladium-catalysed vinylic hydrogen substitution reactions with aryl, benzyl and styryl halides. J Org Chem 1972;37:2320-2322.
30. Meijere AD, Meyer FE. Fine feathers make fine birds: the Heck reaction in modern garb. Angew Chem Int Ed Engl 1994;33: 2379-2411. (Pubitemid 24977304)